Top Ten articles in the pharma industry this week
pharmafile | November 4, 2016 | News story | Medical Communications |Â Â November, news, pharmaceutical, top 10, top ten, top ten storiesÂ
This week has seen pharmaceutical companies release their third quarter profits, good news for some whilst others have attempted to use the release of the news to hide some not-so-positive news. Read here to catch up on this and the other biggest news stories that have been viewed on our website.
10. Hard times continue for Valeant as ex-CEO investigated for fraud
Valeant Pharmaceuticals former CEO, J. Michael Pearson, and CFO, Howard Schiller, could potentially face criminal charges over the company’s actions with Philidor Rx Services regarding accounting revenues.
9. FDA issues warning letter after Chinese firm impedes investigation
The FDA has issued a Chinese firm with a warning letter after claims it intentionally impeded an inspection of its facility in November 2015.
8. MSD’s Alzheimer’s study could break new ground for treatment
MSD, known as Merck in North America, have released encouraging results from a Phase I trial for a drug potentially slowing the mental decline associated with Alzheimer’s disease.
7. Teva sets out to delay generic competitor to Copaxone
Teva submits documents to the FDA regarding the difference in composition between Copaxone 40mg and its generic competitors.
6. NICE approves first new drug for breast cancer in a decade
NICE has approved Halaven for routine treatment, four years after it was rejected. It becomes the first new drug for treatment of metastatic breast cancer for a decade.
5. AstraZeneca’s head and neck cancer treatment clinical trials put on hold
AstraZeneca’s drug is placed on a partial hold in clinical trials due to the increased incidence in bleeding for those patients involved in the trial.
4. FDA rejects Sarilumab due to production facility issues
Regeneron and Sanofi’s rheumatoid arthritis treatment rejected on the basis of issues identified at a Sanofi facility where the drug’s production is finished.
3. Lily increases diabetes drug by 700% over 20 years
A tweet from Vermont Senator Bernie Sanders’ account brought the increase to public attention and sent shares crashing.
2. Gilead quietly drops drugs from line up alongide Q3 results
Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports.
1. Pfizer surprises industry by ending development of projected blockbuster
Pfizer announced, alonside Q3 profit reports, the news that it would no longer be developing an experimental cholesterol lowering drug.
Related Content
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return …
FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products
This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
